Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAtla (BCAB) EBITDA (2020 - 2025)

BioAtla's EBITDA history spans 6 years, with the latest figure at -$9.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 43.03% year-over-year to -$9.3 million; the TTM value through Dec 2025 reached -$59.3 million, up 19.8%, while the annual FY2025 figure was -$59.3 million, 19.8% up from the prior year.
  • EBITDA reached -$9.3 million in Q4 2025 per BCAB's latest filing, up from -$13.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$9.3 million in Q4 2025 to a low of -$37.2 million in Q2 2023.
  • Average EBITDA over 5 years is -$23.4 million, with a median of -$24.0 million recorded in 2021.
  • Peak YoY movement for EBITDA: tumbled 1594.95% in 2021, then surged 67.82% in 2024.
  • A 5-year view of EBITDA shows it stood at -$23.5 million in 2021, then fell by 21.59% to -$28.6 million in 2022, then grew by 0.08% to -$28.5 million in 2023, then skyrocketed by 43.08% to -$16.2 million in 2024, then soared by 43.03% to -$9.3 million in 2025.
  • Per Business Quant, the three most recent readings for BCAB's EBITDA are -$9.3 million (Q4 2025), -$13.8 million (Q3 2025), and -$18.6 million (Q2 2025).